402473-54-5 | 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]Benzenebutanoic acid

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$35.00	$24.00
2mg	98%	in stock	$48.00	$33.00
5mg	98%	in stock	$69.00	$48.00
10mg	98%	in stock	$108.00	$75.00

Description

• Catalog Number: AF60865
• Chemical Name: 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]Benzenebutanoic acid
• CAS Number: 402473-54-5
• Molecular Formula: C24H21FN2O3
• Molecular Weight: 404.4335
• MDL Number: MFCD13184814
• SMILES: N#Cc1ccc(c(c1)NC(=O)C(c1ccc(c2c1cccc2)F)C)CCCC(=O)O

Computed Properties

• Complexity: 660
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 7
• Undefined Atom Stereocenter Count: 1
• XLogP3: 4.4

Literature

• Prostaglandin receptor EP4 in abdominal aortic aneurysms.

  The American journal of pathology 20120701

• Oral administration of prostaglandin E(2)-specific receptor 4 antagonist inhibits lipopolysaccharide-induced osteoclastogenesis in rat periodontal tissue.

  Journal of periodontology 20120401

• Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP(4) receptor.

  Journal of neurochemistry 20120301

• Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells.

  American journal of physiology. Lung cellular and molecular physiology 20120115

• PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.

  Platelets 20120101

• Inhibition of EP4 signaling attenuates aortic aneurysm formation.

  PloS one 20120101

• EP4 receptor as a new target for bronchodilator therapy.

  Thorax 20111201

• The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood.

  Journal of thrombosis and thrombolysis 20110801

• Prostaglandin EP4 receptor enhances BCR-induced apoptosis of immature B cells.

  Prostaglandins & other lipid mediators 20110801

• Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.

  European journal of immunology 20110801

• PGE1 and PGE2 modify platelet function through different prostanoid receptors.

  Prostaglandins & other lipid mediators 20110201

• The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation.

  Arteriosclerosis, thrombosis, and vascular biology 20101201

• Endogenous prostaglandin E2 accelerates healing of indomethacin-induced small intestinal lesions through upregulation of vascular endothelial growth factor expression by activation of EP4 receptors.

  Journal of gastroenterology and hepatology 20100501

• Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.

  Cancer research 20100215

• The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.

  Platelets 20100101

• Orally administered novokinin, an angiotensin AT2 receptor agonist, suppresses food intake via prostaglandin E2-dependent mechanism in mice.

  Peptides 20090601

• PGE2-receptor subtype EP4-dependent adherence of mastocytoma P-815 cells to matrix components in subcutaneous tissues overlaying inside surface of air pouch cavity in CDF1 mouse.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080801

• Prostaglandin E2 induces hypertrophic changes and suppresses alpha-skeletal actin gene expression in rat cardiomyocytes.

  Journal of cardiovascular pharmacology 20071101

• Involvement of prostaglandin E receptor EP3 subtype in duodenal bicarbonate secretion in rats.

  Life sciences 20070606

• Prostaglandin E receptor EP4 antagonist suppresses osteolysis due to bone metastasis of mouse malignant melanoma cells.

  FEBS letters 20070206

• Prostaglandin E2 is required for ultraviolet B-induced skin inflammation via EP2 and EP4 receptors.

  Laboratory investigation; a journal of technical methods and pathology 20070101

• Prostaglandin E2 receptor EP4-selective antagonist inhibits lipopolysaccharide-induced cervical ripening in rabbits.

  Acta obstetricia et gynecologica Scandinavica 20070101

• Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism.

  Cancer research 20061001

• Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.

  Cancer research 20060315

• Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages.

  The Journal of biological chemistry 20060210

• In vivo constriction of the fetal and neonatal ductus arteriosus by a prostanoid EP4-receptor antagonist in rats.

  Pediatric research 20051101

• Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.

  Journal of the American Society of Nephrology : JASN 20050801

• Participation of prostaglandin E receptor EP4 subtype in duodenal bicarbonate secretion in rats.

  American journal of physiology. Gastrointestinal and liver physiology 20040701

• The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut.

  The Journal of clinical investigation 20020401